Balanced news tone
News Sentiment
317450 sentiment intelligence
MYUNGIN PHARM news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
4 relevant articles
News tone and price action are not far from neutral.
62/100 classification confidence.
directly relevant articles
high-authority source matches
+1.3% over one week, -0.2% over four weeks, trend inactive, and below fair value.
Enterprise value to revenue forward of Myung in Pharm Co., Ltd. – KRX:317450
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
62/100 classification
One-week reaction
1.3%
Price digesting
Trend fit
Trend inactive
-0.2% over four weeks
Fair value
-30.1%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
1
Neutral
3
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingView
Direct company coverage
Enterprise value to revenue forward of Myung in Pharm Co., Ltd. – KRX:317450
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 20:32
- Source
- TradingView
koreabiomed.com
Direct company coverage
Myungin Pharm secures global IP rights to Parkinson’s drug Paxroya
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jan 2026 08:00
- Source
- koreabiomed.com
koreabiomed.com
Direct company coverage
Myungin Pharm to debut on Kospi Oct. 1 after strong investor demand
- Tone
- Positive 66/100
- Event
- Macro sensitivity
- Published
- 30 Sep 2025 07:00
- Source
- koreabiomed.com
koreabiomed.com
Direct company coverage
Korea’s CNS leader Myung In Pharm goes Kospi for global deals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Sep 2025 07:00
- Source
- koreabiomed.com